Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.34 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20128707 | 0.90 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HRH3MAOB | |
| SCHEMBL20330100 | 0.84 | SLC6A2 (0.35) | SLC6A2SLC6A4SLC6A3HRH3MAOB | |
| SCHEMBL20128697 | 0.76 | CACNA1H (0.32) | SLC6A2SLC6A4SLC6A3HRH3KCNH2 | |
| SCHEMBL20317394 | 0.74 | CACNA1H (0.31) | HRH3KCNH2CACNA1HCYP2D6 | |
| SCHEMBL21899199 | 0.73 | SLC6A2 (0.46) | SLC6A2SLC6A4SLC6A3HRH3CHRNB2 | |
| SCHEMBL19958983 | 0.72 | SLC6A1 (0.36) | HRH3MAOBKCNH2CACNA1IALDH1A1 | |
| SCHEMBL19958980 | 0.72 | SLC6A1 (0.36) | HRH3MAOBKCNH2CACNA1IALDH1A1 | |
| SCHEMBL19958982 | 0.72 | SLC6A1 (0.36) | HRH3MAOBKCNH2CACNA1IALDH1A1 | |
| SCHEMBL19958985 | 0.72 | SLC6A1 (0.36) | HRH3MAOBKCNH2CACNA1IALDH1A1 | |
| SCHEMBL21456311 | 0.72 | CARM1 (0.39) | SLC6A2SLC6A4SLC6A3HRH3CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | ARVINAS OPERATIONS, INC. | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190151295-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES | IRAK1, IRAK4, IRAK2 | SLC6A2 4852/4885SLC6A4 4330/4885SLC6A3 4683/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | SLC6A2 4852/4885SLC6A4 4330/4885SLC6A3 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.